The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Open accessAbstract
OBJECTIVE: To update the 2004 American Academy of Neurology guideline for managing treatment-resistant (TR) epilepsy with second- and third-generation antiepileptic drugs (AEDs). METHODS: 2004 criteria were used to systemically review literature (January 2003 to November 2015), classify pertinent studies according to the therapeutic rating scheme, and link recommendations to evidence strength. RESULTS: Forty-two articles were included. RECOMMENDATIONS: The following are established as effective to reduce seizure frequency (Level A): immediate-release pregabalin and perampanel for TR adult focal epilepsy (TRAFE); vigabatrin for TRAFE (not first-line treatment); rufinamide for Lennox-Gastaut syndrome (LGS) (add-on therapy). The following should be considered to decrease seizure frequency (Level B): lacosamide, eslicarbazepine, and extended-release topiramate for TRAFE (ezogabine production discontinued); immediate- and extended-release lamotrigine for generalized epilepsy with TR generalized tonic-clonic (GTC) seizures in adults; levetiracetam (add-on therapy) for TR childhood focal epilepsy (TRCFE) (1 month-16 years), TR GTC seizures, and TR juvenile myoclonic epilepsy; clobazam for LGS (add-on therapy); zonisamide for TRCFE (6-17 years); oxcarbazepine for TRCFE (1 month-4 years). The text presents Level C recommendations. AED selection depends on seizure/syndrome type, patient age, concomitant medications, and AED tolerability, safety, and efficacy. This evidence-based assessment informs AED prescription guidelines for TR epilepsy and indicates seizure types and syndromes needing more evidence. A recent Food and Drug Administration (FDA) strategy allows extrapolation of efficacy across populations; therefore, for focal epilepsy, eslicarbazepine and lacosamide (oral only for pediatric use) as add-on or monotherapy in persons ≥4 years of age and perampanel as monotherapy received FDA approval.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baulac, M., Brodie, M. J., Patten, A., Segieth, J., & Giorgi, L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70105-9 · Cited by 186
Trinka, E., Marson, A. G., Van Paesschen, W., Kälviäinen, R., Marovac, J., Duncan, B., Buyle, S., Hallström, Y., Hon, P., Muscas, G. C., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300376 · Cited by 121
Research works printed but not linked: 22
- 10.1212/01.WNL.0000123693.82339.FC · DOI · Paper page
- 10.1212/01.WNL.0000123695.22623.32 · DOI · Paper page
- 10.1212/WNL.52.8.1540 · doi:10.1212/wnl.52.8.1540
- American Academy of Neurology. Clinical Practice Guidelines Process Manual, 2004 ed. St. Paul: The American Academy of Neurology; 2004. Available at: aan.com/Guidelines/Home/UnderDevelopment. Accessed January 30, 2010.
- 10.1212/01.WNL.0000167384.68207.3E · DOI · Paper page
- 10.1111/j.1528-1167.2007.01128.x · DOI · Paper page
- 10.1212/01.wnl.0000252941.50833.4a · DOI · Paper page
- 10.1016/S0140-6736(07)60460-7 · DOI · Paper page
- 10.1016/S0140-6736(98)10531-7 · DOI · Paper page
- 10.1001/archneur.1995.00540340081016 · DOI · Paper page
- 10.1016/S1474-4422(11)70154-5 · DOI
- 10.1111/j.1528-1167.2010.02670.x · DOI
- 10.1016/S0920-1211(99)00039-X · DOI · Paper page
- 10.1016/S0140-6736(95)90581-2 · DOI · Paper page
- 10.1111/j.1528-1157.1999.tb05562.x · DOI · Paper page
- 10.1177/0883073807303997 · DOI
- 10.1016/S0140-6736(07)60461-9 · DOI · Paper page
- 10.1056/NEJMoa0902014 · DOI · Paper page
- 10.1111/epi.12028 · DOI · Paper page
- 10.1212/01.WNL.0000048200.12663.BC · DOI
- 10.1034/j.1600-0404.2003.00093.x · DOI · Paper page
- 10.1016/S0920-1211(97)00025-9 · DOI · Paper page
Cited by
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
Zhang, Y.-J., Guo, Y.-Y., & Wang, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-52532-5 · Cited by 3
Metadata
- Authors
- Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J.
- Venue
- Neurology
- Published
- 2018-07-10
- Volume
- 91
- Issue
- 2
- Pages
- 74-81
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2808405323
- Cited by
- 205
- References
- 2
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. https://app.cochat.ai/papers/10.1212/wnl.0000000000005755
- The paper
- Kanner, A. M., Ashman, E., Gloss, D., Harden, C., Bourgeois, B., Bautista, J. F., Abou-Khalil, B., Burakgazi-Dalkilic, E., Llanas Park, E., Stern, J., Hirtz, D., Nespeca, M., Gidal, B., Faught, E., & French, J. (2018). Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. https://doi.org/10.1212/wnl.0000000000005755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.